Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc
April 1, 2021
Immune-Onc Therapeutics, a California-based cancer immunotherapy firm co-founded by Chinese pharma specialist Charlene Liao, has raised $73 million in Series B1 and B2 rounds of financing, it announced earlier this week.
The latest funding brings the total capital raised by the company to $110 million, it said in a statement.
Beijing-headquartered Oceanpine Capital was the lead investor in the two rounds, which were joined by return backers Northern Light Venture Capital and Vivo Capital. Following the financing, Oceanpine CEO and managing partner Dave Chenn joined the Immune-Onc board of directors.
The biopharma firm’s Series B1 and B2 rounds also attracted a slew of Chinese investors, including South China Venture Capital, Sherpa Healthcare Partners, BOCOM International Holdings, Triwise Capital, Qianzhan Investment, Yanchuang Capital, Tao Capital and Yinglian Healthcare Fund.
Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
2/9/21
Drug Farm, a China- and US-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has completed
financing totaling $56 million USD. This funding will enable the Company to initiate human clinical trials with its lead drug DF-006, a first-in-class, orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases. The financing will also be used to further advance Drug Farm’s additional pipeline candidates for therapies in cancer and autoimmune diseases. Drug Farm investors include BioVeda China Fund (BVCF), WuXi AppTec’s corporate venture fund, South China Venture Capital (SCVC), Detong Capital, and Zhejiang United Investment Group (ZUIG).